Marathon Petroleum Corp 8-K, filed Apr 21, 2022
Marathon Petroleum Corp (MPC)
8-K
2022-04-21
For: 2022-04-21
View Original
Added on
April 08, 2026
About this 8-K
Marathon Petroleum Corp filed this 8-K on April 21, 2022.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 21, 2022
_____________________________________________
(Exact name of registrant as specified in its charter)
_____________________________________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: (419 ) 422-2121
_____________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||
Emerging growth company ☐
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ||
☐
| Item 8.01 | Other Events. | ||||
On April 21, 2022, Michael J. Hennigan, President and Chief Executive Officer of Marathon Petroleum Corporation, issued a letter to colleagues and shareholders informing them of a recently diagnosed medical condition. A copy of his letter is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. | ||||
(d) Exhibits.
Exhibit Number | Description | |||||||
| Letter from Michael J. Hennigan, President and Chief Executive Officer of Marathon Petroleum Corporation | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Marathon Petroleum Corporation | |||||||||||
| Date: April 21, 2022 | By: | /s/ Molly R. Benson | |||||||||
| Name: Molly R. Benson | |||||||||||
| Title: Vice President, Chief Securities, Governance & Compliance Officer and Corporate Secretary | |||||||||||
Exhibit 99.1
A MESSAGE FROM MICHAEL J. HENNIGAN
April 21, 2022
Dear Colleagues and Shareholders,
Our team has navigated many challenges. We addressed them head on and have been very successful. Today, I am confronted with a personal challenge. Through a recent health physical, it was discovered that I have a tumor in my throat. The good news is that it was caught early and is curable. Tests have confirmed the cancer is limited to my throat and nearby lymph nodes. I have come to understand this type of cancer is relatively common and I am optimistic based on the very encouraging prognosis I’ve received from leading medical institutions.
Following consultation with my doctors, I will soon be undergoing a seven-week treatment protocol that includes a combination of radiation and chemotherapy. This standard of care has been very successful in curing this type of cancer. I have been advised that I will be able to continue my active involvement in our business during my treatment, including running the company as chief executive. I do expect to limit travel during my treatment. Further, given the nature of throat cancer and the treatment process, I may limit speaking at times simply to avoid stressing my throat. Our Board of Directors has been fully apprised of my condition and is very supportive.
I feel good, am confident in my treatment plan and look forward to having this chapter behind me. We have accomplished a great deal together and the outlook is bright. I want to thank all our employees for what they do every day to deliver results and make our company successful. Thanks also for your continuing support.
Mike